Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RARA | P10276 | 17/20 | 0.76 |
| ▸ | RARB | P10826 | 17/20 | 0.76 |
| ▸ | RARG | P13631 | 16/20 | 0.76 |
| ▸ | RXRA | P19793 | 1/20 | 0.76 |
| ▸ | NR2E1 | Q9Y466 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7807984 | 1.00 | RARA (0.76) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL8664433 | 0.89 | RARB (0.58) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7807099 | 0.89 | RARB (0.60) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7807093 | 0.89 | RARB (0.60) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6755033 | 0.86 | RARA (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6755036 | 0.86 | RARA (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL29613352 | 0.86 | RARA (1.00) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL7807980 | 0.85 | RARB (0.54) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6238262 | 0.84 | RARB (0.83) | RARARARBRARGRXRANR2E1 | |
| SCHEMBL6238257 | 0.84 | RARB (0.83) | RARARARBRARGRXRANR2E1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6319948-B2 | PREVENTION AND/OR MINIMIZATION OF SURGICAL ADHESION FORMATION BY ADMINISTERING CERTAIN SUBSTITUTED (5,6)-DIHYDRONAPHTHALENYL COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY | 2001-11-20 | — | — | US | disclosed |
| US-20010003780-A1 | Retinoid antagonists and uses thereof | TRAMPOSCH KENNETH M (US) | 2001-06-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010003780-A1 | Retinoid antagonists and uses thereof | RARA, RARB, RARG | RARA 1/4885RARB 2/4885RARG 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.